Exelixis $EXEL announced encouraging results from a Phase 1 study of CABOMETYX (cabozantinib) in combination with nivolumab [Bristol-Myers Squibb�s $BMY Opdivo] in patients with previously treated genitourinary tumors. The data will be presented on Sunday, October 9 at the European Society for Medical Oncology 2016 Congress in Copenhagen.